AIM: To study if HER-2 overexpression by locally advanced esophageal cancers increase the chance of brain metastasis following esophagectomy. METHODS: We retrospectively reviewed the medical records of esophageal cancer patients who underwent esophagectomy at University of Iowa Hospitals and Clinics between 2000 and 2010. Data analyzed consisted of demographic and clinical variables. The brain metastasis tissue was assayed for HER-2 overexpression utilizing the FDA approved DAKO Hercept Test(®). RESULTS: One hundred and forty two patients were reviewed. Median age was 64 years (36-86 years). Eighty eight patients (62%) received neoadjuvant chemoradiotherapy. Pathological complete and partial responses were achieved in 17 (19%) and 71 (81%) patients. Cancer relapsed in 43/142 (30%) patients. The brain was the first site of relapse in 9/43 patients (21%, 95% CI: 10%-36%). HER-2 immunohistochemistry testing of the brain metastasis tissue showed that 5/9 (56%) cases overexpressed HER-2 (3+ staining). CONCLUSION: HER-2 overexpression might be associated with increased risk of brain metastasis in esophageal cancer patients following esophagectomy. Further studies will be required to validate this observation.
AIM: To study if HER-2 overexpression by locally advanced esophageal cancers increase the chance of brain metastasis following esophagectomy. METHODS: We retrospectively reviewed the medical records of esophageal cancerpatients who underwent esophagectomy at University of Iowa Hospitals and Clinics between 2000 and 2010. Data analyzed consisted of demographic and clinical variables. The brain metastasis tissue was assayed for HER-2 overexpression utilizing the FDA approved DAKO Hercept Test(®). RESULTS: One hundred and forty two patients were reviewed. Median age was 64 years (36-86 years). Eighty eight patients (62%) received neoadjuvant chemoradiotherapy. Pathological complete and partial responses were achieved in 17 (19%) and 71 (81%) patients. Cancer relapsed in 43/142 (30%) patients. The brain was the first site of relapse in 9/43 patients (21%, 95% CI: 10%-36%). HER-2 immunohistochemistry testing of the brain metastasis tissue showed that 5/9 (56%) cases overexpressed HER-2 (3+ staining). CONCLUSION:HER-2 overexpression might be associated with increased risk of brain metastasis in esophageal cancerpatients following esophagectomy. Further studies will be required to validate this observation.
Authors: Z T Hammoud; K A Kesler; M K Ferguson; R J Battafarrano; A Bhogaraju; N Hanna; R Govindan; A A Mauer; M Yu; L H Einhorn Journal: Dis Esophagus Date: 2006 Impact factor: 3.429
Authors: Thomas W Rice; Deepak Khuntia; Lisa A Rybicki; David J Adelstein; Michael A Vogelbaum; David P Mason; Sudish C Murthy; Eugene H Blackstone Journal: Ann Thorac Surg Date: 2006-12 Impact factor: 4.330
Authors: Howard Safran; Thomas Dipetrillo; Paul Akerman; Thomas Ng; Devon Evans; Margaret Steinhoff; David Benton; John Purviance; Lisa Goldstein; Umadevi Tantravahi; Teresa Kennedy Journal: Int J Radiat Oncol Biol Phys Date: 2006-11-09 Impact factor: 7.038
Authors: Nishi Kothari; Eric Mellon; Sarah E Hoffe; Jessica Frakes; Ravi Shridhar; Jose Pimiento; Ken Meredith; Nam D Tran; Nadia Saeed; Khaldoun Almhanna Journal: J Gastrointest Oncol Date: 2016-08
Authors: Devarati Mitra; Jeffrey W Clark; Helen A Shih; Kevin S Oh; Priscilla K Brastianos; Jennifer Y Wo; Matthew R Strickland; William T Curry; Aparna R Parikh; Ryan B Corcoran; David P Ryan; A John Iafrate; Darrell R Borger; Jochen K Lennerz; Theodore S Hong Journal: Oncologist Date: 2018-10-29
Authors: J Feilchenfeldt; Z Varga; M Siano; H I Grabsch; U Held; B Schuknecht; A Trip; T Hamaguchi; P Gut; O Balague; K Khanfir; J Diebold; W Jochum; H Shoji; R Kushima; D Wagner; Y Shimada; A Cats; A Knuth; H Moch; S Aebi; S Hofer Journal: Br J Cancer Date: 2015-08-27 Impact factor: 7.640